Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by recurrent bacterial infections, hypogammaglobulinemia and low to normal numbers of circulating B cells. Mutations in the ICOS, TACI and CD19 genes have recently been identified in o10% of CVID patients. We, herein, describe two novel CD19 gene disruptions in an 8-year-old Japanese boy, who had been clinically diagnosed as having CVID at the age of 5 years. Flow-cytometric analysis demonstrated absence of CD19 and reduced CD21 expression on CD20-postive peripheral blood B cells. Mutation analysis of CD19 revealed a mutation in the splice acceptor site of intron 5 (IVS5-1G4T) of the maternal allele, resulting in skipping of exon 6, and a truncated protein product. The paternal allele was disrupted by a gross deletion encompassing at least the ATP2A1, CD19 and NFATC2IP genes. The patient had a small number of IgD À CD27 þ memory B cells, in which somatic mutation were detected. His B cells showed substantial proliferation upon stimulation, but reduced IgG and IgA production in vitro. These findings extend the mutation spectrum of the CD19 deficiency to four, and confirm the homogeneity of the CD19 deficiency as a unique type of CVID.
Introduction
Common variable immunodeficiency (CVID) is the most common primary immunodeficiency that requires clinical attention with an incidence of 1:10 000 to 1:50 000. 1 It is a type of primary antibody-deficiency syndrome, which is characterized by susceptibility to bacterial infections, hypogammaglobulinemia and low to normal numbers of circulating B cells. 2 CVID is a heterogeneous group of disorders, and diagnosis is mainly made by means of exclusion from other immunodeficiency diseases, such as X-linked agammaglobulinemia, 3, 4 hyper -IgM syndrome 5 or X-linked lymphoproliferative syndrome. 6, 7 However, in several CVID patients, mutations in genes involved in B-cell differentiation are thought to be affected. Recent studies demonstrated that in some CVID patients genetic defects in the ICOS, TACI and CD19 genes underlie the antibody deficiency. [8] [9] [10] [11] Whereas TACI is affected in B8% of CVID patients, 8, 9 mutations in ICOS and CD19 are thought to be very rare. 10, 11 CD19 is a member of the Ig superfamily expressed on the surface of B lymphocytes, and may play a pivotal role in B-cell differentiation and activation. 12 On mature B cells, the protein complex consisting of CD19, CD21, CD81 and CD225, signals in conjunction with the B-cell antigen receptor upon antigen encounter, and is necessary to decrease the threshold for receptordependent signaling. 12, 13 Recently, four hypogammaglobulinemic patients from two unrelated families were shown to have defective CD19, resulting from mutations in the CD19 gene. 11 Due to an impaired antibody response and memory B-cell formation, these patients developed an immunodeficiency in the first decade of life. We, herein, describe a new case of CD19 deficiency with two novel mutations in the CD19 gene. In spite of two novel mutations, the immunological and clinical phenotypes are in line with previous observations. The CD19 deficiency appears to be homogeneous and well-defined antibody deficiency.
Results

Identification of the CD19 defects
The exclusion of known genetically identifiable immunodeficiencies is necessary for diagnosis of CVID. 14 In light of this current notion, we attempted to immunologically and genetically re-evaluate a young male CVID patient. The patient had normal numbers of CD20-positive peripheral blood B cells, but two-color flow-cytometric analysis revealed the lack of CD19 membrane expression ( Figure 1a) . This raised the possibility that the patient had a CD19 deficiency. Furthermore, the level of CD19 expression in the mother was lower than that in the control, suggesting that the mother might be a carrier. In addition, expression of CD19-complex member CD21 was also slightly reduced on the patient's B cells as compared with that of a healthy control (Figure 1b) . Mutation analysis of the patient's CD19 gene disclosed a seemingly homozygous mutation at the splice acceptor site of intron 5 (IVS5-1G4T) (Figure 2a ). CD19 transcript analysis showed that the mutation caused skipping of exon 6, and coupling of exons 5-7 ( Figure 2b) . As a result, the frame of exon 7 is shifted, leading to a truncated protein with four altered amino acids and a premature stop codon at position 320, prior to all conserved intracellular tyrosine residues ( Figure 2c ).
As expected, the mother was heterozygous for mutated allele (Figure 2a ). The father, however, did not carry a mutated allele (Figure 2a ). This raised the question whether the second allele of the patient was disrupted by a de novo mutation, or it contained a gross deletion including the mutation site. In order to confirm the latter hypothesis, DNA fluorescence in situ hybridization analysis using a CD19-specific probe was performed. Although two signals for the CD19 gene were detected in the metaphases from a healthy control (Figure 3a) , only one signal was detected in cells from the patient (Figure 3b ). In addition, fluorescence in situ hybridization analysis was performed for the neighboring genes ATP2A1 and NFATC2IP. The control samples revealed two signals for ATP2A1 and NFATC2IP genes (Figures 3c and e) , whereas the patient samples revealed only one signal for ATP2A1 and NFATC2IP genes (Figures 3d and f) . Thus, the patient carries an allele that contains a gross deletion of at least 68.5 kbp including the ATP2A1, CD19 and NFATC2IP genes. Because no additional material could be obtained from the father, it remains unclear whether the gross genomic deletion in the patient was a de novo event or inherited from his father.
Memory B-cell sub-population Similar to most CVID patients, the previously described CD19-deficient patients show decreased numbers of IgD
Ig class-switched memory B cells. 11, 15, 16 Substantial numbers of Ig class-switched memory B cells were detectable, though reduced as compared to healthy controls, in peripheral blood of our patient, suggesting some potential to undergo class-switch recombination (Figure 4a ).
To examine whether B cells of the patient were capable of undergoing somatic hypermutation, V H 5-Cm transcripts were studied. Six out of 13 individual clones revealed somatic hypermutations (Figure 4b ). The frequency of somatic hypermutations was 0.94% (normal adults 1.8%70.4, and cord blood 0.07%70.01), and was indicative of the potential to form an antigen-selected B-cell receptor repertoire.
B-cell antigen response
In agreement with previous observations, 11 our clinical and immunological findings of the patient suggested that the CD19 deficiency appeared to result in an impaired antigen response by B cells. To quantify the B-cell response in our patient, we employed two in vitro (Figure 5a ). In vitro Ig production showed reduced IgA and IgG production of patient's B cells after stimulation with CD40L and CD40L þ IL-10, whereas IgM production was similar to a healthy control.
Discussion
In this study we describe a CD19-deficient patient, who was compound heterozygous for two novel mutations. Similarly to two previously identified disrupted CD19 alleles, 11 these mutations lead to loss of CD19 membrane expression, and result in an antibody-deficiency syndrome, characterized by recurrent (mainly) bacterial infections.
The mutation in the splice acceptor site of exon 6 (IVS5-1G4T) results in skipping of exon 6, placing exon 7 out-of frame after exon 5, which leads to a premature stop codon at the intracellular amino acid 320. The resulting protein product is almost similar to the product resulting from the 972insA mutation identified before. 11 In line with this, the patient's B cells completely lack membrane CD19 expression. Furthermore, the lack of all intracellular domains responsible for signal transduction makes any expressed protein non-functional. 17 The other mutated allele contained a gross deletion that involved ATP2A1, CD19, NFATC2IP and potentially more genes. In addition to the CD19 gene deletion, the patient lacks one allele of the ATP2A1 and NFATC2IP genes. Mutations in the ATP2A1 gene that encodes SERCA1 are associated with Brody disease, an inherited disorder of skeletal muscle function. 18 The patient did not show clinical symptoms suggestive of Brody disease. Furthermore, mutations in ATP2A1 are associated with an autosomal recessive inheritance, making it likely that the other allele compensates for the loss. The exact function of the protein encoded by NFAT2CIP is not known. However, similar to ATP2A1, it is likely that the loss of one allele does not have clinical consequences.
The clinical presentation of the patient was very similar to the other four reported CD19-deficient patients, 11 making it a rather homogeneous disorder. All patients presented with clinical symptoms of antibody deficiency in the first decade of life and showed reduced serum Ig levels. In addition, all patients show an impaired antibody response after vaccination. Whereas normal numbers of peripheral blood B cells are found, they all show a marked decrease in memory B cells. In spite of decreased number, these memory B cells do show molecular signs of antigen-dependent differentiation. Finally, considering the thrombocytopenia in our patient, the CD19 deficiency might be associated with the development of autoimmune disease. We, herein, described the fifth case in the world of a patient with CD19 deficiency, resulting from two novel mutations in the CD19 gene. The clinical and immunological characteristics of the patient were similar to four recently identified cases of CD19 deficiency. These observations support the idea that CD19 deficiency is a distinct and unique subset of CVID. Our finding and the recent observation of a CD21 deficiency 19 suggest that defects in antigen recognition, resulting from mutations in CD19-complex members (CD19, CD21, CD81 and CD225) might be identified in more patients that suffer from an antibody deficiency.
Patients, materials and methods
Patient's report
The patient was an 8-year-old Japanese boy born to non-consanguineous healthy parents who had no family , IgD o0.6 mg dl À1 and IgE 9.0 U ml À1 ), and the immunological tests demonstrated CD3 62.7% (1775 ml À1 ), CD4 37.6% (1064 ml À1 ), CD8 27.6% (781 ml
À1
) and CD20 19.0% (538 ml À1 ) in peripheral blood lymphocytes. Antibodies against measles, rubella, tetanus and pertussis toxin were not detectable, although the patient had been vaccinated. Since the patient had normal numbers of B cells in his blood, he was clinically diagnosed to have CVID, and thus was treated with intravenous immunoglobulinreplacement therapy. In addition, he had also been recently diagnosed with a mild thrombocytopenia that did not require medical attention. The patient is now doing well with intravenous immunoglobulin-replacement therapy.
Flow-cytometric analysis of B cells
Heparinized venous blood was obtained from the patient and his parents after obtaining the written informed Figure 3 The patient is heterozygous for a gross deletion involving the CD19, ATP2A1 and NFATC2IP gene. FISH analysis with CD19-(a and b), ATP2A1-(c and d) and NFATC2IP-specific probes (e and f) and the chromosome 16-specific D16Z3 probe in a healthy control (a, c and e) and the patient (b, e and f). In both a healthy control and the patient, two signals per cell were found with D16Z3 (green signals; indicated by arrowheads). Whereas the control also showed two signals for the CD19, ATP2A1 and NFATC2IP probes, only one signal was found for each of these in the patient (red signals; indicated by arrows). FISH, fluorescence in situ hybridization. consent. Peripheral blood B cells were assessed by twocolor flow-cytometric analysis employing CD19-PE, CD20-ECD (phycoerythrin-Texas Red), and CD21-fluorescein isothiocyanate (FITC) mAbs (all from Beckman Coulter, Marseille, France) and CD20-FITC mAb (DAKO Japan, Kyoto, Japan). In addition, the naive and memory B-cell sub-populations were evaluated by three-color analysis with a combination of FITC goat anti-IgD Ab (Southern Biotechnology Associates Inc., Birmingham, AL, USA), CD27-PE mAb (Becton Dickinson, Mountain View, CA, USA), and CD20-ECD mAb as described previously. 20 Mutation analysis of the CD19 gene Peripheral blood mononuclear cells (PBMC) were collected after Ficoll-Hypaque gradient centrifugation of total blood. DNA was extracted from PBMC using a QIAamp Blood Kit (Qiagen GMBH, Hilden, Germany), and was subjected to PCR. All of the coding exons and splice sites of the CD19 gene were amplified, and a sequencing reaction was carried out with the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an automated ABI PRISM 310 DNA Sequencer (Applied Biosystems). The PCR primers used for amplification of the CD19 gene are listed in Table 1 . RNA was extracted from PBMC using a TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), and was subjected to reverse transcription PCR. A fragment of the CD19 cDNA was amplified from the first-strand cDNA with primer pairs encompassing exon 6 (5 0 -AGGGGCCTAAGTCATTGCTG-3 0 and 5 0 -TGCCCA AGGTTGGAGTCGTT-3 0 ) and sequenced to verify the mutation found in the genomic DNA.
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR ----------------------------------------------------------------------------------------------------------------------------------------------------------------------I -------------------------N ----------------------------------------------------------------------------------R ------------------------------------W ---------------C --------------W -D -S --Y -N-------H ------------------------------------------------------------------------------------------------------------------------------Y -I --------Q A --------W ---------------C --------------W -D -S --Y -N -------H -------------------------------
Fluorescence in situ hybridization analysis of the CD19 gene PBMC stimulated in culture with phytohemagglutinin (PHA) for 72 h were treated with a 0.075 M KCl solution and fixed with Carnoy's solution (3:1 methanol and acetic acid) for metaphase preparation. A CD19-specific genomic probe (11 517 bp) was prepared by LA-PCR Kit (Takara, Kyoto, Japan) with primer pairs encompassing exons 1 and 15 (5 0 -CTGTTCTCAAAGACATTCTGGTG CAGG-3 0 and 5 0 -TGCTTAGAACATAGTAAGGTCGGG CACT-3 0 ). In addition, probes were designed to label the ATP2A1 gene, which is located 30 kbp upstream of CD19, and the NFATC2IP gene, which is located 14 kbp downstream of CD19. The ATP2A1-and NFATC2IP-specific genomic probes (7045 and 6017 bp) were also prepared by LA-PCR Kit with primers encompassing exons 10 and 14 (5 0 -GGTTCAAGTGGCTCACCTTGTTACCA AC-3 0 and 5 0 -GGTTCAAGTGGCTCACCTTGTTACCA AC-3 0 ) and exons 3 and 7 (5 0 -CTTGCAGCTGCCATAGT TAGTTAGGACA-3 0 and 5 0 -CAATTCAGACTTCTAGGC TCCAGAAGTG-3 0 ), respectively. For fluorescence in situ hybridization analysis, denatured metaphase spreads were hybridized with the probes labeled with digoxigenin-11-dUTP using nick translation kit (Roche Diagnostics KK, Tokyo, Japan). The Spectrum Green-labeled chromosome 16 probe (D16Z3, Vysis, Tokyo, Japan) was used as a control. The CD19-, ATP2A1-and NFATC2IP-specific probes were detected with anti-digoxigenin rhodamine (Roche Diagnostics KK) providing a red signal, whereas D16Z3 was detected by a green signal. Metaphases were counterstained with 4 0 ,6-diamino-2-phenylindole dihydrochloride, and the images of the hybridization were captured under fluorescence microscopy (Olympus Optical Co., Tokyo, Japan). At least 20 metaphases were observed in each setting.
B-cell proliferation assay B cells were isolated from PBMC using a magnetic cell sorter (MACS; Miltenyi Biotech GMBH, Bergisch Gladbach, Germany) by negative selection according to the experiment procedure. Re-analysis showed that more than 97% of the purified cells were CD20 positive. The purified B cells were cultured in the presence of 0.01% Staphylococcus aureus Cowan I (Sigma-Aldrich Inc., St Louis, MO, USA) and 50 U ml À1 recombinant human (rh) IL-2 (Takeda Co., Osaka, Japan), or 5 mg ml À1 CpG (InvivoGen, San Diego, CA, USA) at a final cell density of 2.5 Â 10 5 ml À1 in a volume of 200 ml per well. The cells were cultured in 96-well round-bottomed plates for 3 days at 371C in a humidified atmosphere with 5% CO 2 . The cells were pulsed with 0.5 mCi (18.5 Bq) [ Ig production assay Ig production was assessed by an ELISPOT assay as described elsewhere. 21, 22 First, the dendritic cells were derived from in vitro cultures of the human cord blood CD34 þ cells. Briefly, the CD34 þ cells were isolated from 1  AGGAGGCAAGTGTTGTGAGT  GCCACAACTCAAGTTTCCAG  2  TGCTCTATAACCTGGTGTGA  TGCCCACCTAGCTCCGAGTT  3  TTTCACCTCTTCAGTTTCCC  TTTCACCTCTTCAGTTTCCC  4  GGGGAAACTGAAGAGGTGAA  TTCCACTTCTTCCCAGTACC  5  TCTCAGGATTGGGACGTAAG  TGGGAAGATGGAGTAGGGT  6  CCTGTCTCCTTTGTTGAACC  CCAAGGAGTTCTTCACAGAG  7  CTTCTGAAGGCCTGGACAGA  ACAGCGGATTGGAGGGATGA  8  AGACCCAGAGTCCATTCGCA  CCACTATTCGGGCCACAGAC  9-10  TCTGTGGCCCGAATAGTGGA  GGATCCCCTTCTAGGAGTGT  11-12  AATTGCAGCGCTGTGACACT  TGAGAGGAGTCACAGGATTG  13  CCTCAGTCTTCCTCCTTACC  AGGCTGGAAGGCAAATGTCAG  14 ACTTTGCCTTCCAGCCTACT GTGTGAATCTTGGGGACTTG the human cord blood cells through positive cell selection using MACS. The CD34 þ cells were then cultured in the presence of 100 ng ml À1 rhGM-CSF (R&D Systems Inc., Minneapolis, MN, USA), 2.5 ng ml À1 rhTNF-a (R&D Systems Inc.), and 25 ng ml À1 rh stem cell factor (R&D Systems Inc.) in a RPMI-1640 medium supplemented with 10% fetal calf serum, gentamicin and penicillin G sodium. The dendritic cells were harvested after 12-14 days of culture. B cells isolated from peripheral blood of the patient and a healthy control were cultured at 1 Â 10 5 ml À1 alone or in the presence of 1 Â 10 5 ml À1 irradiated (3400 rad) dendritic cells and 3.75 Â 10 4 ml À1 irradiated (7000 rad) CD40 ligand-transfected L cells (a gift from Dr Yong-Jun Liu, DNAX, Palo Alto, CA, USA) in a final volume of 200 ml. To each well, rhIL-10 (R&D Systems Inc.) was added at a concentration of 200 ng ml
À1
. The cells were used on the sixth day for the ELISPOT assay.
IgG, IgA and IgM secretion of the B cells was detected by an ELISPOT assay after 6 days of culture using the Millipore Multiscreen Assay System (Millipore Corp., Billerica, MA, USA). The plates were precoated by 100 ml per well of a goat anti-human capture antibody (Southern Biotechnology Associates Inc.) at a concentration of 10 mg ml À1 in phosphate-buffered saline overnight at 41C Cultured B cells were added to the plate after washing in phosphate-buffered saline-Tween and were re-suspended in RPMI-1640, and incubated at 371C for 20 h. After discarding the cells, the plate was washed and 100 ml per well biotinylated detection antibody in phosphate-buffered saline with 0.5% bovine serum albumin was added. The plate was then incubated at 371C for 2 h. Next, the plate was washed and 100 ml per well of avidin-enzyme complex in phosphate-buffered saline (VECTASTATIN Elite ABC Kit, Vector Laboratories Inc., Burlingame, CA, USA) was added, and incubated for 1 h at room temperature. After washing, 100 ml avidin-enzyme complex substrate (Sigma-Aldrich Inc., St Louis, MO, USA) was added per well for 4 min. Spot development was stopped under tap water. The plate was left to dry overnight in a dark place. The spots were counted using a computer-aided ELISPOT manual counting system (ELIPHOTO, Minerva Biolabs GMBH, Berlin, Germany).
Analysis of somatic hypermutations
Total RNA was isolated from purified patient B cells, and reverse-transcribed into cDNA using the oligo dT primer and Superscript II Reverse Transcriptase (Invitrogen). V H 5-Cm transcripts were amplified using a V H 5 leader forward primer (5 0 -ATGGGGTCAACCGCCATCCT-3 0 ) and a Cm constant region reverse primer (5 0 -GTCCTGTGCGAGGCAGCCAA-3 0 ). 20 The PCR products were ligated into the pCR2.1 vector (Invitrogen) and transformed into TOP10F' bacteria (Invitrogen). Individual clones were selected, and plasmid DNA was purified. Next, DNA sequencing was performed with a dideoxy termination technique using an ABI 377 sequencer (Applied Biosytems).
